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Abstract
Background: Hepatic leiomyosarcomas are rare soft-tissue tumours. The majority of lesions previously
considered as leiomyosarcomas have been identified as gastrointestinal stromal tumours (GISTs). Con-
sequently, understanding of the role of liver resection for true leiomyosarcoma is limited, a fact that is
exacerbated by the increasing recognition of leiomyosarcoma subtypes. This study presents data on the
outcomes of liver resection for leiomyosarcoma and suggests an algorithm for its pathological assess-
ment and treatment.
Methods: Patients were identified from a prospectively collected departmental database. All tumours
were negative for c-kit expression. Immunohistochemistry was performed to identify the presence of
oestrogen or progesterone receptor (OR/PR) expression or Epstein–Barr virus (EBV) and patients were
stratified according to this profile.
Results: Eight patients (of whom seven were female) underwent a total of 11 liver resections over a
12-year period. One patient had a primary hepatic leiomyosarcoma. Of those with metastatic
leiomyosarcomas, the primary tumours were located in the mesentery, gynaecological organs and
retroperitoneum in four, two and one patient, respectively. Both leiomyosarcomas of gynaecological origin
stained positive for OR/PR expression. One patient had previously undergone renal transplantation; this
leiomyosarcoma was associated with EBV expression. Median survival was 56 months (range: 22–132
months) and eight, six and four patients remained alive at 1, 3 and 5 years, respectively.
Conclusions: Hepatic resection for leiomyosarcoma is associated with encouraging rates of 5-year
overall and disease-free survival. The worse outcome that had been expected based on data derived from
historical cohorts (partly comprising subjects with GIST) was not observed. An algorithm for pathological
classification and treatment is suggested.
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Introduction
For common liver tumours, such as colorectal liver metastases
(CLM), longterm outcomes in large patient cohorts have been
comprehensively reported.1 Experiences of treating patients with
non-colorectal, non-neuroendocrine tumours are, however, much
less common. Understanding the role of surgical intervention in
primary or metastatic hepatic leiomyosarcoma is complicated by
the low prevalence of the disease and the evolution of the patho-
logical understanding of smooth muscle tumours (SMTs), of
which leiomyosarcoma is one type.2
Several case series have described the outcomes of patients
undergoing resection of hepatic leiomyosarcoma.3–7 Although sur-
vival does not mirror the experience of patients treated for CLM,
an increase in survival over non-operated patients is observed and
cure is possible. The identification of gastrointestinal stromal
tumours (GISTs) as a distinct subtype of SMT, however, requires
the careful reinterpretation of previously reported series. The
This study was presented in part as a poster at the 10th World IHPBA
Congress, 1–5 July 2012, Paris.
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histological features of GIST and leiomyosarcoma are similar and
the two entities are separated by analysis for c-kit proto-oncogene
expression. The less aggressive growth pattern of GIST and its
potential for treatment with tyrosine kinase inhibitors renders this
a clinically important distinction. A review of previously pub-
lished series of patients submitted to resection of hepatic
leiomyosarcoma has attempted to estimate the respective propor-
tions of GISTs and true hepatic leiomyosarcomas.7 A further series
described outcomes in patients with hepatic GIST and
leiomyosarcoma.3 However, this series recruited patients prior to
the identification of c-kit expression and did not explain its
method of identifying patients with GIST or leiomyosarcoma.8
Evolution in the pathological description of abdominal
leiomyosarcoma has led to the recognition of subtypes related to
Epstein–Barr virus (EBV) infection and oestrogen and/or proges-
terone receptor (OR/PR) expression. The purposes of this study
are to report the outcomes of liver resection amongst patients with
true leiomyosarcoma, to review the histology of these cases and to
suggest an approach to the identification and treatment of the
different forms of leiomyosarcoma.
Materials and methods
Adult patients submitted to resection of hepatic leiomyosarcoma
at a single institution between 1999 and 2010 were retrospectively
identified from a prospectively maintained database. Patient
demographic details, investigations, treatments, complications,
pathological variables, and outcomes (survival and disease-free
status) were identified.
Pathological specimens were re-evaluated for this study by a
pathologist with a specialist interest in SMTs (WM). Cases were
included if they were negative for CD 117 (c-kit) expression and
positive for smooth muscle actin and desmin, thereby confirming
leiomyosarcoma as the tumour type. The Trojani system was used
to grade the samples. To further sub-classify tumours, immuno-
histochemistry (IHC) was performed to assess OR/PR expression
and quantitative polymerase chain reaction (PCR) analysis was
conducted to identify EBV within archived tissue. Positive and
negative controls were included.
Results
Group demographic details and primary disease
Over 12 years, 11 of a series of 2397 hepatic resections (0.46%)
were performed for leiomyosarcoma. These procedures were con-
ducted in eight patients (range per patient: 1–3 resections). The
median age at initial presentation was 58 years (range: 40–71
years). Seven of the patients were women. Primary leiomyo-
sarcoma originated from the bowel or mesentery (n = 4), gynae-
cological organs (n = 2) or retroperitoneum (n = 1); there was a
single case of primary hepatic leiomyosarcoma. The median inter-
val between primary leiomyosarcoma and identification of meta-
static hepatic leiomyosarcoma was 29 months (range: 6–58
months). Table 1 provides a summary of each patient’s history.
Hepatic disease
The median number of segments resected was two (range: 1–7
segments). Complications affected three patients; two required a
second operation to control haemorrhage, and one suffered tem-
porary liver dysfunction with cholestasis and ascites. The median
length of hospital stay was 11 days (range: 7–28 days). There were
no postoperative deaths (within 90 days).
Survival
At 1, 3 and 5 years, eight, six and four patients, respectively,
remained alive. Seven, five and three patients, respectively,
remained disease-free at these time-points. All deaths were
caused by disease prior to these time-points. Of the four patients
alive at 5 years, two subsequently died (one of disease) and two
remained alive (one with disease). The median survival was 56
months (range: 22–132 months) and the median disease-free
survival was 46.5 months (range: 11–132 months). Six resections
were associated with an R0 resection margin, in one of which
local recurrence occurred. Five resections were associated with
an R1 resection margin and four of these were affected by local
recurrence.
Histological assessment
All tumours demonstrated characteristic features (Figs 1 and 2)
and positivity for smooth muscle actin and desmin (Fig. 3). Seven
were metastatic leiomyosarcomas of Trojani grade 1 (n = 2), grade
2 (n = 2) and grade 3 (n = 3). Two tumours were positive for OR
expression (Fig. 4). The solitary primary hepatic leiomyosarcoma
displayed features of a low-grade tumour with much less cellular
atypia than metastatic leiomyosarcoma and was positive for EBV
expression as assessed by PCR (Fig. 5). This patient had under-
gone previous renal transplantation and was receiving immuno-
suppressive therapy.
Discussion
This study aimed to present the outcomes of patients undergoing
surgical treatment for primary and metastatic hepatic leiomyo-
sarcomas in light of the identification of distinct subtypes of
leiomyosarcoma and is the first to do so. This follows the realiza-
tion that GIST is a distinct pathological type of SMT that can be
distinguished from leiomyosarcoma, typically, by expression of
the proto-oncogene c-kit, CD117.8 Patients with metastatic GIST
have more favourable outcomes than those with leiomyo-
sarcoma as a result of the medical therapies available.6,9 Conse-
quently, previous studies describing outcomes following resection
of hepatic ‘leiomyosarcoma’ may be unreliable because they
included unknown or estimated numbers of patients with GIST.3–7
Despite the aggressive nature of leiomyosarcoma, patients in the
present cohort demonstrated encouraging survival outcomes not
dissimilar to those demonstrated by patients with resected CLM.
The study is weakened by its small patient cohort, although this
may reflect careful patient selection. However, several patients
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Figure 1 Histopathology of a section of a leiomyosarcoma (not
otherwise specified) demonstrates spindle cell malignancy with
zones of necrosis typical of this tumour. (Haematoxylin and eosin
stain; original magnification ×200)
Figure 2 Histopathology at higher magnification of a leiomyo-
sarcoma (not otherwise specified) demonstrates mitosis, interlacing
fascicles, pink cytoplasm and central cigar-shaped nuclei. (H&E
stain; ×400)
Figure 3 Immunohistochemistry for desmin shows strong cytoplas-
mic positivity typically seen in smooth muscle. (Original magnifica-
tion ×50)
Figure 4 Immunohistochemistry in a leiomyosarcoma of gynaeco-
logical origin shows positivity for nuclear oestrogen receptor expres-
sion (Original magnification ×400)
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underwent extensive hepatic resection or multivisceral resec-
tion, which suggests the patient cohort was not comprised of
patients with favourable outcomes prior to initial liver resec-
tion. Obtaining an R0 resection margin appears to relate to
disease-free survival and should be achieved when possible. An
R1 resection margin does not exclude disease-free survival, but
should stimulate intensive radiological follow-up as repeat
resection is feasible.
The Trojani histological grade was assessed in all cases. This
did not seem to impact on survival, which indicates that even
patients with high-grade tumoursmay benefit from surgical
resection. The description of three distinct subtypes of hepatic
leiomyosarcoma has clinical relevance. Assessment for OR
nuclear expression and EBV status should be performed to
stratify cases. In the present series, leiomyosarcoma of the con-
ventional type was the most prevalent form.
The expression of OR was identified in two patients; the major-
ity of primary tumours arise in the smooth muscle of the gynaeco-
logical tract, which is sensitive to oestrogen, and have OR
expression. Most benign tumours are positive for OR, but with
malignant progression this can be lost.Medical therapy targeted at
the hormone receptor status of these tumours is of unclear clinical
benefit. The use of aromatase inhibitors in advanced uterine
leiomyosarcoma has shown promise in small case series,10,11 but a
partial response to treatment was observed in only three of a larger
cohort of 24 patients.12 In another study, a response was observed
in just one of 28 patients with uterine leiomyosarcoma treated
with tamoxifen.13
The single case of EBV leiomyosarcoma in this series illustrates
typical features of this disease; it is a rare tumour14 characterized
by its development following a period of immunosuppression.
This occurs in two settings in, respectively, patients with human
immunodeficiency virus (HIV) infection15–17 and in those with
immunosuppression following solid organ transplantation.18–23
Immunosuppression appears to be the key regulator of leiomyo-
sarcoma EBV disease progression. Rapid growth of hepatic
leiomyosarcoma EBV was observed following liver transplanta-
tion in a 2-year-old child.18 Immunosuppression was subsequently
reduced and then withdrawn in line with the lack of progression
of leiomyosarcoma. At 12 years following transplantation, the
patient was found to be symptom-free. Thus the reduction or
withdrawal of immunosuppression should be considered when
possible. Figure 6 proposes a classification and treatment algo-
rithm for SMTs.
Figure 5 Polymerase chain reaction analysis (PCR) is positive for
Epstein–Barr virus (EBV). *EBV is detected (dilution 1/5, 1/10 and
1/20) in patient 8 as confirmed by the positive and negative controls.
The positive control is indicated by the arrow
Smooth muscle tumour 
Leiomyosarcoma 
Leiomyosarcoma – not otherwise specified
GIST 
Leiomyosarcoma –
EBV-related 
Leiomyosarcoma –
gynaecological
Surgical
resection 
Surgical
resection 
Surgical 
resection 
Surgical 
resection 
Imatinib /
alternative 
Consider reducing
immunosuppression 
Consider aromatase
inhibitor 
+ve 
+ve 
+ve 
-ve 
-ve 
-ve 
c-kit
expression 
EBV
expression 
OR/PR
expression 
Figure 6 Proposed algorithm for the pathological classification and management of abdominal smooth muscle tumours (SMTs) based upon
histological assessment. Immunohistochemistry permits the stratification of SMTs into subgroups with implications for the patient's clinical
management whereby gastrointestinal stromal tumours (GISTs) and gynaecological leiomyosarcomas may be treated with medical therapy,
and Epstein–Barr virus (EBV)-related leiomyosarcoma by modifying immunosuppression. Primary and metastatic disease should be treated
by surgical resection where possible. OR/PR, oestrogen/progesterone receptor
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Conclusions
Hepatic resection of leiomyosarcoma is associated with encourag-
ing rates of 5-year overall and disease-free survival. The worse
outcome predicted on the basis of findings in historical cohorts
(partly comprising subjects with GIST) was not observed.
Immunohistochemistry characterizes subgroups of leiomyosar-
coma as of gynaecological origin, EBV-related and as not other-
wise specified. The potential roles of hormonal therapy and the
modulation of immunosuppression in the first two subtypes are
yet to be fully explored. Although hepatic leiomyosarcoma is a
rare entity, the proposed algorithm provides a contemporary
classification and strategy for the management of hepatic
leiomyosarcoma.
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